Details for New Drug Application (NDA): 213586
✉ Email this page to a colleague
The generic ingredient in UZEDY is risperidone. There are thirty drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the risperidone profile page.
Summary for 213586
Tradename: | UZEDY |
Applicant: | Teva |
Ingredient: | risperidone |
Patents: | 9 |
Suppliers and Packaging for NDA: 213586
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586 | NDA | Teva Pharmaceuticals USA, Inc. | 51759-305 | 51759-305-10 | 1 SYRINGE, GLASS in 1 CARTON (51759-305-10) / .14 mL in 1 SYRINGE, GLASS |
UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586 | NDA | Teva Pharmaceuticals USA, Inc. | 51759-305 | 51759-305-11 | 1 SYRINGE, GLASS in 1 CARTON (51759-305-11) / .14 mL in 1 SYRINGE, GLASS |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | Strength | 50MG/0.14ML (50MG/0.14ML) | ||||
Approval Date: | Apr 28, 2023 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Apr 28, 2026 | ||||||||
Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Jan 12, 2025 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Subscribe | Patent Expiration: | Nov 12, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF SCHIZOPHRENIA |
Complete Access Available with Subscription